Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04300062

Acronym

REBIMMUNE

Enrollment

Registered

2020-03-09

Start date

2020-08-18

Completion date

2027-08-31

Last updated

2025-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

lung cancer, rebiopsy, immunotherapy, progression

Brief summary

The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI. The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.

Detailed description

The study will consist of creation a tumor tissue bank, all sampling will be stored in the biological resources center of Ambroise Paré hospital.

Interventions

PROCEDURERebiopsy

Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosed NSCLC or SCLC; * Patient treated priorly by ICI and progressed under ICI; * Have provided written informed consent for the study; * Be \>/= 18 years of age on day of signing informed consent.

Exclusion criteria

* Patient under guardianship or curatorship; * Unable to provide written informed consent for the study; * Technical impossibility to carry out tissular rebiopsy under local anesthesia.

Design outcomes

Primary

Measure	Time frame	Description
Incidence of specific histomolecular resistance	At the end of study, up to 2 years	Banking of tumor samples at progression with immune checkpoint inhibitor (ICI) in lung cancer, to evaluate the incidence of specific histomolecular resistance mechanisms to ICI by immunohistochemistry and molecular testing.

Countries

France

Contacts

Primary ContactEtienne Giroux Leprieur, MD, PhD

etienne.giroux-leprieur@aphp.fr+33 1 49 09 58 02

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026